Combining the VA-GFR model with other predictive tools, such as the RENSAFE AKI and CKD nomogram [26] for RN cases or Cystatin C [27] in DN cases, may help reduce the risk of unexpected low NB-GFR occurrences. This evidence concerns the gene CST3 and liver dysplastic nodule.